Galectin治疗 GALT 深 沪
已收盘 07-02 16:00:00 美东时间
4.51
+0.180
+4.16%
华盛通- 最 高4.775
- 今 开4.38
- 成交量 72.29万股
- 最 低 4.3597
- 昨 收 4.33
- 总市值 2.97亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 1.10%
- 52周最低 2.025
- 委 比 45.89%
- 总股本 6585.69万
- 历史最高 19.11
- 量 比 0.30
- 振 幅 9.59%
- 历史最低 0.49
- 每 手 1
- 风险率 1.21%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Top 3 Health Care Stocks That May Keep You Up At Night In June
As of June 30, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices ...
06-30 20:55
美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Galectin暴涨21.79% 这家生物科技公司突破200日阻力位实现逆势上涨
核心事件：生物科技标的半乳糖凝集素（GALT）单日大涨21.79%，本次行情为纯技术面驱动的个股独立行情，无对应公司或板块层面的基本面利好消息刺激，属于投机资金...
06-24 00:36
Galectin Therapeutics Announces Positive Feedback From Recent In Person Type C Meeting With FDA For Its Belapectin To Treat Patients With Metabolic Dysfunction-associated Steatohepatitis Cirrhosis, Portal Hypertension
Galectin Therapeutics Inc. (NASDAQ: GALT), a biotechnology company focused on developing therapies for patients with advanced liver disease, today announced positive feedback from its recent in person Type C meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of bela...
06-23 20:09
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertension Galectin Therapeutics reported FDA Type C meeting alignment to advance belapectin into a Phase 3 trial for MASH cirrhosis with portal hypertension. No new clinical results were presented; the
06-23 19:51
Galectin Therapeutics Q1 EPS $(0.08) Misses $(0.06) Estimate
Galectin Therapeutics (NASDAQ:GALT) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 46.67 percent increase over losses of $(0.15) per
05-15 20:13
Galectin Therapeutics Q1 FY26 net loss narrows to $5.1 million
Galectin Therapeutics Q1 FY26 net loss narrows to $5.1 million Galectin Therapeutics posted Q1 net loss applicable to common stockholders of $5.1 million, or $(0.08) per share, narrowing from a $9.6 million loss, or $(0.15) per share, a year earlier. R&D expense fell to $2.2 million from $6.5 millio
05-15 19:51
Galectin net loss narrows 47.61% to $5.05 million in Q1 FY26
Galectin net loss narrows 47.61% to $5.05 million in Q1 FY26 Galectin Therapeutics posted a net loss of USD 5.05 million, or USD 0.08 per share, for quarter ended March 31, 2026, narrowing from a net loss of USD 9.63 million, or USD 0.15 per share, a year earlier. Operating loss narrowed to USD 4.08
05-15 19:47
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Galectin Therapeutics, Inc. reported progress on its belapectin program targeting galectin-3 in MASH cirrhosis, with positive biomarker data from the NAVIGATE trial showing reduced liver stiffness and slower disease progression. The company plans to present additional findings at EASL and meet with the FDA. Financially, as of Q1 2026, the company had $14.1 million in cash and a $10 million credit line, sufficient for operations through May 2027. ...
05-15 12:00
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
Argenx reported $1.3 billion in Q1 2026 product net sales, up 63% YoY, with VYVGART driving growth. The PDUFA date for anti-AChR antibody negative gMG is May 10, 2026. Key highlights include advancing FcRn leadership in rheumatology, progressing empasiprubart in MMN, and expanding the pipeline with ten molecules in clinical development. The company also announced Karen Massey as CEO and expanded its presence in China. Financial results showed a 1...
05-07 05:00
